AstraZeneca’s Imfinzi plus Imjudo combined with lenvatinib and TACE show significant improvement in progression-free survival in embolisation eligible unresectable liver cancer in EMERALD-3 Phase III trial

Astarzeneca announces their new positive high-level results from the EMERALD-3 Phase III trial showed AstraZeneca’s Imfinzi in combination with Imjudo , lenvatinib and transarterial chemoembolisation demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival versus TACE alone for patients with unresectable hepatocellular carcinoma eligible for embolisation.

Note that patients in the investigational arms were treated with the STRIDE regimen with or without lenvatinib, before TACE, and then alongside TACE. Although not formally tested at this time, data for the treatment arm evaluating the STRIDE regimen plus TACE versus TACE alone showed strong trends toward improved PFS and OS.

Ghassan Abou-Alfa, MD, JD, MBA, PhD(hc), Attending Physician, Professor of Medicine at Memorial Sloan Kettering Cancer Center, and principal investigator in the trial said, “Dual immunotherapy with durvalumab and tremelimumab in the STRIDE regimen represents a meaningful advance for patients with embolisation-eligible liver cancer, who currently lack systemic treatment options to keep their cancer from progressing or recurring, with a trend of improving survival. EMERALD‑3 shows we can now significantly reduce the risk of disease progression with STRIDE as the immunotherapy backbone alongside lenvatinib and TACE.”

Susan Galbraith, Executive Vice President, Oncology Haematology R&D, AstraZeneca, said: “EMERALD‑3 now shows that bringing the dual immunotherapy STRIDE regimen earlier, alongside TACE and lenvatinib, can further improve outcomes in earlier‑stage liver cancer. This builds on the HIMALAYA Phase III trial data in patients with advanced, unresectable disease, where the STRIDE regimen has already demonstrated durable overall survival benefit. We are discussing these positive data with global regulatory authorities while awaiting the final results from the key secondary endpoints.”

 

---

---

Related Topics and Keywords

EMERALD-3 Phase III trial, Imfinzi, imjudo, lenavtinib, liver cancer, tace